JMP Securities Initiates Coverage on Aimmune Therapeutics Inc. (AIMT)
Equities researchers at JMP Securities assumed coverage on shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) in a report released on Monday. The firm set an “outperform” rating and a $30.00 price target on the stock. JMP Securities’ price objective suggests a potential upside of 93.67% from the stock’s previous close.
Several other brokerages also recently issued reports on AIMT. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Friday, September 23rd. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, September 12th. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, September 21st. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $35.00 price objective on shares of Aimmune Therapeutics in a research report on Friday, August 19th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Aimmune Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $32.20.
Aimmune Therapeutics (NASDAQ:AIMT) opened at 15.49 on Monday. The company has a 50 day moving average price of $14.91 and a 200-day moving average price of $13.60. The firm’s market cap is $654.51 million. Aimmune Therapeutics has a 52-week low of $9.77 and a 52-week high of $26.50.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.01. Equities research analysts anticipate that Aimmune Therapeutics will post ($1.75) EPS for the current year.
In other news, insider Mary M. Rozenman sold 30,000 shares of the business’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $16.80, for a total transaction of $504,000.00. Following the completion of the sale, the insider now owns 30,000 shares in the company, valued at $504,000. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 24.56% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. increased its stake in Aimmune Therapeutics by 94.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 51,994 shares of the company’s stock worth $563,000 after buying an additional 25,278 shares during the last quarter. American Century Companies Inc. increased its stake in Aimmune Therapeutics by 4.5% in the second quarter. American Century Companies Inc. now owns 98,261 shares of the company’s stock worth $1,063,000 after buying an additional 4,201 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Aimmune Therapeutics by 116.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 20,796 shares of the company’s stock worth $225,000 after buying an additional 11,179 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in Aimmune Therapeutics during the second quarter worth approximately $230,000. Finally, Parametric Portfolio Associates LLC increased its stake in Aimmune Therapeutics by 23.4% in the second quarter. Parametric Portfolio Associates LLC now owns 48,270 shares of the company’s stock worth $522,000 after buying an additional 9,156 shares in the last quarter. Institutional investors own 68.87% of the company’s stock.
About Aimmune Therapeutics
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.